Journals A-Z
All Subjects
Free Journals
sciepub.com
World Journal of Organic Chemistry
ISSN (Print): 2372-2150 ISSN (Online): 2372-2169 Website: https://www.sciepub.com/journal/wjoc Editor-in-chief: Subrata Shaw
Open Access
Journal Browser
Go
Issue 2, Volume 1
Article Metrics
  • 26098
    Views
  • 18042
    Saves
  • 8
    Citations
  • 41
    Likes
Export Article
World Journal of Organic Chemistry. 2013, 1(2), 14-19
DOI: 10.12691/wjoc-1-2-2
Open AccessReview Article

Rifampin and Their Analogs: A Development of Antitubercular Drugs

Mohammad Asif1,

1Department of pharmacy, GRD (PG) Institute of Management & Technology, Dehradun, India

Pub. Date: May 01, 2013
View Full Text Full Text PDF (189 KB) Full Text ePUB(76 KB)

Cite this paper:
Mohammad Asif. Rifampin and Their Analogs: A Development of Antitubercular Drugs. World Journal of Organic Chemistry. 2013; 1(2):14-19. doi: 10.12691/wjoc-1-2-2

Abstract

There has been considerable interest in various analogues of antitubercular drugs particularly against multidrug and extensively drug resistant tuberculosis because mycobacterium species has developed resistant against available drugs. The currently used antitubercular also causes some serious toxic effects and also require long period of therapy for the treatment. Therefore, various new drugs and analogues of currently used antitubercular drugs were prepared with minimum side effects or effective against multidrug and extensively drug resistant strains of tuberculosis. In present review we discussed about brief introduction of tuberculosis followed the rifampicin and their analogues which are effective against tuberculosis.

Keywords:
multidrug resistance mycobacterium tuberculosis rifanpicine analogues

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

Figure of 1

References:

[1]  Asif, M., 2012. Study of clinically used and recently developed antimycobacterial agents. Orient Pharm Exp Med, 12: pp. 15-34.
 
[2]  World Health Organization. Strategic framework to decrease the burden of TB/HIV documents WHO/CDS/TB. 2002; 296, WHO/HIVAIDS/2002, 2. Geneva, Switzerland: World Health Organization.
 
[3]  World Health Organisation, Tuberculosis, Fact Sheet No. 104, 2007. http:// www.who.int/mediacentre/factsheets/who104/en/index.html/.
 
[4]  WHO report 2008: The Stop TB Strategy, case reports, treatment outcomes and estimates of TB burden. http://www.who.int/tb/publications/global_report/2008/annex_3/en/index.html.
 
[5]  Asif, M., Siddiqui, A.A., Husain, A., 2012. Quinolone derivatives as antitubercular drugs. Med Chem Res, 22(3): 1029-1042.
 
[6]  Kamal, A., Azeeza, S., Malik, M.S., Shaik, A.A., and Rao, M.V. 2008. Efforts Towards the Development of New Antitubercular Agents: Potential for Thiolactomycin Based Compounds. J Pharm Pharmaceut Sci, 11 (2): 56s-80s.
 
[7]  Nahid, P., Pai, M., and Hopewell, P.C. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc 2006; 3: 103-10.
 
[8]  Nguyen, L., and Thompson, C.J., 2006. Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol, 14: 304-12.
 
[9]  WHO, 2005. Global tuberculosis control-surveillance, planning, financing (Geneva: World Health Organization).
 
[10]  World Health Organization (WHO). Treatment of tuberculosis: guidelines for national programmes. 3rd edition. 2003. Geneva.
 
[11]  Tripathi, R.P., Tewari, N., Dwivedi, N., and Tiwari, V.K., 2005. Fighting tuberculosis: An old disease with new challenges. Med Res Rev., 25: 93-131.
 
[12]  Bastian, I., and Colebunders, R., 1999. Treatment and prevention of multidrug-resistant tuberculosis. Drugs, 58(4), 633-661.
 
[13]  Ahmad, Z., Sharma, S., Khuller, GK., Singh, P., Faujdar, J., and Katoch, VM. 2006. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis. Inter J Antimicrob Agents, 28(6): pp. 543-544.
 
[14]  Aldrich, C. C., Bosshoff, H. I., and Remmel R. P., 2010. Antitubercular agents, In: Burger's Medicinal Chemistry, Drug Discovery and Development, vol. 7 Antiinfectives, Abraham, Understanding Tuberculosi-D. J. & Rotella, D. P. (Eds.), 7th ed., pp.713-812, Wiley, New York.
 
[15]  Management of MDR-TB. A field guide A companion document to Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402, WHO Library Cataloguing-in-Publication Data: World Health Organization, 2009.
 
[16]  Center for Disease Control. "Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs—Worldwide, 2000-2004". 2006, 55: 301-305.
 
[17]  Grosset, J. H., 1992. Treatment of tuberculosis in HIV infection. Tuber Lung Dis, 73: 378-383.
 
[18]  Centers for Disease Control and Prevention. 1982. Adverse drug reactions among children treated for tuberculosis. M.M.W.R. Morb. Mortal. Wkly. Rep., 29: 589-591.
 
[19]  Cole, ST., and Alzari, P. M. 2007. Towards new tuberculosis drugs. Biochemical Society Transactions, 35(5): pp. 1321-1324.
 
[20]  Glickman, S. W., Rasiel, E. B., Hamilton, C. D., Kubataev, A., and Schulman, K. A., 2006. Medicine. A portfolio model of drug development for tuberculosis. Science, 311, 1246-1247.
 
[21]  Stahlmann R, Lode H. Toxicity of quinolones. Drugs, 1999, 58(Suppl. 2):37-42.
 
[22]  Rieder, H.L., Arnadottir T., Trebucq A, and Enarson, D.A., 2001. Tuberculosis treatment: dangerous regimens? Inter J Tuberculosis & Lung Diseases. 5: pp. 1-3.
 
[23]  Russell, D. G., 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol, 2: 569-577.
 
[24]  Smith, C. V., Sharma, V., and Sacchettini, J. C., 2004. TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis, 84, 45-55.
 
[25]  O'Brien, R. J., and Nunn, P. P. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med, 2001, 163, 1055-1058.
 
[26]  Paramasivan, C. N., Sulochana, S., Kubendiran, G., Venkatesan, P., and Mitchison, D. A. 2005. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 49: 627-631.
 
[27]  Somoskovi, A., Parsons, L. M., and Salfinger, M., 2001. The molecular basis of resistance to Isoniazid, Rifampin, and Pyrazinamide in Mycobacterium tuberculosis. Respir. Res., 2: 164-168.
 
[28]  Farr, B.F. Rifamycins. In, Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 5th ed. (Mandell, G.L., Bennett, J.E., and Dolin, R., eds.) Churchill Livingstone, Philadelphia, 2000, pp. 348-361.
 
[29]  Temple, M.E., Nahata, M.C. Rifapentine: its role in the treatment of tuberculosis. Annals of Pharmacotherapy, 1999, 33(11):1202-1210.
 
[30]  Zhang, Y., 2004. Persistent and dormant tubercle bacilli and latent tuberculosis. Frontiers Bioscience, 1(9): pp. 1136-1156.
 
[31]  Baciewicz, A.M., Self, T.H., and Bekemeyer, W.B., 1987. Update on rifampin drug interactions. Arch. Intern. Med., 147: 565-568.
 
[32]  Cauthen, G.M., Kilburn, J.O., Kelly, G.D., and Good, R.C. Resistance to anti-tuberculosis drugs in patients with and without prior treatment: survey of 31 state and large city laboratories, 1982-1986. Am. Rev. Respir. Dis., 1988, 137(suppl):260.
 
[33]  Wade, M. M., and Zhang, Y., 2004. Mechanism of drug resistance in Mycobacterium tuberculosis. Frontiers in Bioscience, 9(1), pp.975-994.
 
[34]  Zhang, Y., and Amzel, L M., 2002. Tuberculosis drug targets. Current Drug Targets, 3(2): pp. 131-154.
 
[35]  Zhang, Y., Post-Martens, K., and Denkin, S., 2006. New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today, 11(1): pp. 21-27.
 
[36]  Tomioka, H., Namba, K., 2006. Development of antitubercular drugs: current status and future prospects, Kekkaku (Japanese Journal)., 81 (12): 753-774.
 
[37]  Zierski, M., and Bek, E., 1980. Side effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. Tubercle, 61(1): pp.41-49.
 
[38]  Gray, M.A., 1997. Tuberculosis Drugs. Orthopaedic Nursing, 16(4): 64-69.
 
[39]  Gangadharam, P.R. Isoniazid, rifampin, and hepatotoxicity. Am. Rev. Respir. Dis., 1986, 133:963-965.
 
[40]  Warrington, R.J., Hogg, G.R., Paraskevas, F., and Tse, K.S., 1977. Insidious rifampin-associated renal failure with light-chain proteinuria. Arch. Intern. Med., 137: 927-930.
 
[41]  Zhang, Y., 2005. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol, 45: 529-564.
 
[42]  Garay, S. M. 2004, In Tuberculosis, W. N. a. G. Rom, S.M., ed. (Philadelphia: Lippincott Williams & Wilkins), 345-394.
 
[43]  Gutierrez-Lugo M-T, Bewley CA. Natural Products, Small Molecules, and Genetics in Tuberculosis Drug Development. J. Med. Chem. 51(9), 2606-2612 (2008).
 
[44]  Janin, Y.L. 2007. Antituberculosis drugs: Ten years of research. Bioorg. Med. Chem. 15(7): 2479-2513.
 
[45]  Figueiredo, R., Moiteiro, C., Medeiros, M.A. et al., 2009. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H37Rv, MDR and NRP Mycobacterium tuberculosis. Bioorg. Med. Chem. 17(2): 503-511.
 
[46]  Dickinson, J.M., and Mitchison, D. A., 1987. In vitro activity of new rifamycins against rifampicin-resistant M. Tuberculosis and mais-complex Mycobacteria. Tubercle, 68:183-193.
 
[47]  Shoen, C. M., DeStefano, M. S., and Cynamon, M. H.2000. Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection. Clin Infect Dis, 30 Suppl 3, S288-290.
 
[48]  Moghazeh, S. L., Pan, X. S., Arain, T. M., Stover, C. K., and Musser, J. M. Comparative antimycrobial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Antimicrob Agents Chemother, 1996, 40, 2655-2657.
 
[49]  Hidaka, T. 1999. Current status and perspectives on the development of rifamycin derivative antibiotics. Kekkaku, 74 (1): 53-61.
 
[50]  Velayati, A. A., Masjedi, M. R., Farnia, P., Tabarsi, P., Ghanavi, J., Ziazarifi, A. H., and Hoffner, S. E., 2009. Emergence of new forms of totally drug-resistant tuberculosis bacilli: Super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest, 136(2): pp.420-425.
 
[51]  Vinšová, J., and Krátký, M., 2010. Tuberculosis - The development of new MDR-TB drugs, In: Drug-Resistant Tuberculosis, Causes, Diagnosis and Treatments, Nguy, S. & K’ung, Z. (Eds.), pp.59-141, Nova Science Publishers, ISBN 978-1-60876-055-8, New York.
 
[52]  Berning, S.E., 2001. The role of fluoroquinolones in tuberculosis today, Drugs. 61: 9-18.
 
[53]  Pasquato KFM, Ferreira EI. An approach for the rational design of new antitubercular agents. Current Drug Targets. 2001, 2: 427-437.
 
[54]  Katz, A. H.; Caufield, C. E. 2003: Structure-based design approaches to cell wall biosynthesis inhibitors. Curr. Pharm. Design. 9: 857-866.
 
[55]  Blanchard, J.S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis. Annu. Rev. Biochem., 1996, 65:215-239.
 
[56]  Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., and Dye, C. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med, 163, 1009-1021.
 
[57]  Espinal MA. The global situation of MDR-TB. Tuberculosis. 2003, 83: 44-51.
 
[58]  Paramasivan, C. N., Sulochana, S., Kubendiran, G., Venkatesan, P., and Mitchison, D. A. 2005. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 49: 627-631.
 
[59]  Russell, D. G., 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol, 2: 569-577.
 
[60]  Smith, C. V., Sharma, V., and Sacchettini, J. C., 2004. TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis, 84, 45-55.
 
[61]  Sunduru, N., Sharma, M., and Chauhan P.M.S., 2010. Recent advances in the design and synthesis of Heterocycles as anti-tubercular agents. Future Med Chem, 2(9): 1469-1500.
 
Manuscript template